김동완 (서울대학교병원) | 한빛사논문 > 한빛사

한빛사논문, 상위피인용논문

조회2,080

서울대학교병원

CV File 93 kb

Lancet Oncol., Available online 11 March 2016 | doi:10.1016/S1470-2045(15)00614-2 Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Dong-Wan Kim, MD^a, Ranee Mehra, MD^b, Daniel S W Tan, MD^c, Enriqueta Felip, MD^d, Laura Q M Chow, MD^e, Prof D Ross Camidge, MD^f, Prof Johan Vansteenkiste, MD^g, Prof Sunil Sharma, MD^h, Tommaso De Pas, MDⁱ, Gregory J Riely, MD^j, Benjamin J Solomon, MBBS^k, Prof Jurgen Wolf, MD^l, Prof Michael Thomas, MD^m, Prof Martin Schuler, MDⁿ, Geoffrey Liu, MD^o, Prof Armando Santoro, MD^p, Santosh Sutradhar, PhD^q, Siyu Li, PhD^q, Tomasz Szczudlo, MD^q, Alejandro Yovine, MD^r, Dr Alice T Shaw, MD^s

^a Seoul National University Hospital, Seoul, Korea

^b Fox Chase Cancer Center, Philadelphia, PA, USA

^c National Cancer Center, Singapore, Singapore

^d Vall d'Hebron University, Barcelona, Spain

^e University of Washington, Seattle, WA, USA

^f University of Colorado, Denver, CO, USA

^g University Hospital KU Leuven, Leuven, Belgium

^h Huntsman Cancer Institute, Salt Lake City, UT, USA

ⁱ Istituto Europeo di Oncologia, Milan, Italy

^j Memorial Sloan Kettering Cancer Center, New York, NY, USA

^k Peter MacCallum Cancer Center, Melbourne, VIC, Australia

^l Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany

^m Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitatsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany

ⁿ University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany

^o Princess Margaret Cancer Center, Toronto, ON, Canada

^p IRCCS Institute Clinico Humanitas, Milan, Italy

^q Novartis Pharma, East Hanover, NJ, USA

^r Novartis Pharma AG, Basel, Switzerland

^s Massachusetts General Hospital, Boston, MA, USA

Correspondence to: Dr Alice T Shaw, Massachusetts General Hospital, Boston, MA 02114, USA

Abstract

Background

ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably develops, often with progression in the brain. Ceritinib is a more potent ALK inhibitor than crizotinib in vitro, crosses the blood-brain barrier in vivo, and shows clinical responses in patients with crizotinib-resistant disease. We aimed to assess whole-body activity of ceritinib in both ALK inhibitor-pretreated and ALK inhibitor-naive patients with ALK-rearranged NSCLC.

Methods

ASCEND-1 was an open-label, phase 1 trial that recruited patients from 20 academic hospitals or cancer centres in 11 countries in Europe, North America, and Asia-Pacific. Eligible patients were aged 18 years or older with ALK-rearranged locally advanced or metastatic cancer that had progressed despite standard therapy (or for which no effective standard therapy existed), who had at least one measurable lesion at baseline. The primary objective (to determine the maximum tolerated dose) has been reported previously. This updated analysis includes all patients with ALK-rearranged NSCLC given oral ceritinib at the recommended dose of 750 mg/day in the dose-escalation and expansion phases. Here we report the secondary outcomes of overall response, duration of response, and progression-free survival, analysed in all patients who received at least one 750 mg dose of ceritinib. Exploratory analyses included retrospective analysis of intracranial activity by independent neuroradiologists, in patients with untreated or locally treated neurologically stable brain metastases at baseline. Safety was assessed in all patients who received at least one dose of ceritinib. This study is no longer recruiting patients; however, treatment and follow-up are ongoing. This study is registered with ClinicalTrials.gov, number NCT01283516.

Findings

Between Jan 24, 2011, and July 31, 2013, 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC. At data cutoff (April 14, 2014), median follow-up was 11·1 months (IQR 6·7-15·2) and 147 (60%) patients had discontinued treatment, 98 (40%) as a result of disease progression. An overall response was reported in 60 (72% [95% CI 61-82]) of 83 ALK inhibitor-naive patients and 92 (56% [49-64]) of 163 ALK inhibitor-pretreated patients. Median duration of response was 17·0 months (95% CI 11·3-non-estimable [NE]) in ALK inhibitor-naive patients and 8·3 months (6·8-9·7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18·4 months (95% CI 11·1-NE) in ALK inhibitor-naive patients and 6·9 months (5·6-8·7) in ALK inhibitor-pretreated patients. Of 94 patients with retrospectively confirmed brain metastases and at least one post-baseline MRI or CT tumour assessment, intracranial disease control was reported in 15 (79% [95% CI 54-94]) of 19 ALK inhibitor-naive patients and in 49 (65% [54-76]) of 75 ALK inhibitor-pretreated patients. Of these 94 patients, 11 had measurable brain lesions and no previous radiotherapy to the brain, six of whom achieved a partial intracranial response. Serious adverse events were recorded in 117 (48%) of 246 patients. The most common grade 3-4 laboratory abnormalities were increased alanine aminotransferase (73 [30%] patients) and increased aspartate aminotransferase (25 [10%]). The most common grade 3-4 non-laboratory adverse events were diarrhoea and nausea, both of which occurred in 15 (6%) patients. Two on-treatment deaths during the study were deemed to be related to study drug by the investigators, one due to interstitial lung disease and one as a result of multiorgan failure that occurred in the context of infection and ischaemic hepatitis.

Interpretation

The durable whole-body responses reported, together with the intracranial activity, support a clinical benefit for treatment with ceritinib in patients with ALK-rearranged NSCLC who have received crizotinib, or as an alternative to crizotinib. A confirmatory phase 2 clinical trial is ongoing to assess ceritinib activity in patients with ALK-rearranged NSCLC and brain or leptomeningeal metastases.

Funding

Novartis Pharmaceuticals Corporation.

논문정보

형식Research article
게재일2016년 03월 (BRIC 등록일 2016-03-16)
연구진국내+국외 연구진
분야 의약학 > 종양의학
피인용횟수120회 이상 인용된 논문 (상위피인용논문 등록일 2020-05-27)

댓글 작성 로그인

CV 열람하기

연락처 보기